Hypercalcemia mediated by parathyroid hormone-related protein in chronic myeloid leukemia. 1994

Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006934 Hypercalcemia Abnormally high level of calcium in the blood. Milk-Alkali Syndrome,Hypercalcemias,Milk Alkali Syndrome,Syndrome, Milk-Alkali
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D044162 Parathyroid Hormone-Related Protein A ubiquitously expressed, secreted protein with bone resorption and renal calcium reabsorption activities that are similar to PARATHYROID HORMONE. It does not circulate in appreciable amounts in normal subjects, but rather exerts its biological actions locally. Overexpression of parathyroid hormone-related protein by tumor cells results in humoral calcemia of malignancy. Hypercalcemic Hormone of Malignancy,PTH Like Tumor Factor,PTH-Like Protein,PTH-Related Peptide,PTHrP,Parathyroid Hormone Like Tumor Factor,Parathyroid Hormone-Like Protein,Parathyroid Hormone-Related Peptide,Tumor Hypercalcemic Factor,Hormone-Related Protein, Parathyroid,Hypercalcemic Factor, Tumor,PTH Like Protein,PTH Related Peptide,Parathyroid Hormone Like Protein,Parathyroid Hormone Related Peptide,Parathyroid Hormone Related Protein

Related Publications

Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
February 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
October 1993, Leukemia,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
October 1997, Cancer,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
May 2011, Pediatric nephrology (Berlin, Germany),
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
June 1995, The Journal of clinical investigation,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
January 1998, Hormone research,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
January 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
January 1999, The Netherlands journal of medicine,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
January 2000, Clinica chimica acta; international journal of clinical chemistry,
Y Sasaki, and T Takahashi, and R Tsuyuoka, and K Tanaka, and H Ishida, and K Nakao, and C Shigeno, and K Nakamura, and M Kozuki, and H Okada
August 1994, Leukemia & lymphoma,
Copied contents to your clipboard!